T.-Y. Kim

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda et al. · Annals of Oncology · 2019 · 191 citations

Ph Iii Study, Hepatology, Medicine +10

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

K. Park, Johan Vansteenkiste, Ki Hyeong Lee et al. · Annals of Oncology · 2020 · 111 citations · Full text

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma

Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh et al. · Annals of Oncology · 2016 · 76 citations · Full text

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Ignacio Melero, Thomas Yau, Yoon‐Koo Kang et al. · Annals of Oncology · 2024 · 64 citations · Full text

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS

Y.H. Park, Elżbieta Senkus, Seock‐Ah Im et al. · Annals of Oncology · 2020 · 60 citations · Full text

Nursing, Breast Oncology, Early Breast Cancer +9